Detalhe da pesquisa
1.
Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR).
Oncologist
; 26(7): 560-e1103, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33829609
2.
An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.
Oncologist
; 24(2): 202-210, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30190302
3.
A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors.
Invest New Drugs
; 31(3): 714-23, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23054206
4.
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial.
Commun Med (Lond)
; 3(1): 120, 2023 Sep 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37684373
5.
Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial.
JAMA Oncol
; 8(5): 740-747, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35357396
6.
Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105.
Mol Cancer Ther
; 17(10): 2248-2256, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29997150
7.
Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer.
Cancer Med
; 3(3): 580-91, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24574330
8.
An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.
Clin Cancer Res
; 20(23): 5918-26, 2014 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25261556
9.
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.
Clin Cancer Res
; 18(17): 4820-9, 2012 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22767667
10.
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
J Clin Oncol
; 26(11): 1810-6, 2008 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-18347007